Targeting accelerated progress at the IPAC-RS Nasal Innovation Forum 2025
Explore how Nanopharm presented strategies for accelerating patient-centric nasal product development at the IPAC-RS Nasal Innovation Forum 2025. Dive into key insights on regulatory science, advanced bioequivalence methods, and targeted drug delivery.
Aligning Alternative Bioequivilence with U.S. FDA: Advancing aerosol dose collection to enhance in vitro dissolution studies
Discover how Nanopharm’s DissoHale system advances aerosol dose collection and dissolution testing to support FDA-aligned alternative bioequivalence for OIDPs.
GDUFA: FDA adds further weight to modelling and simulation’s role in bioequivalence
GDUFA 2026: FDA strengthens role of modeling & simulation for inhaled generic drug bioequivalence. Learn how this shift enhances efficiency for OINDP development.
Optimizing OINDP Regulatory Paths With Model Master Files (MMF)
Streamline OINDP regulatory submissions with Model Master Files—confidential, reusable models that accelerate drug development and U.S. FDA review.
Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs
Aptar Pharma discusses Physiologically based PK models for OINDPs.
Nanopharm’s SmartTrack: Accelerating OINDP Respiratory Drug Delivery
Revolutionize your OINDP respiratory drug delivery with Nanopharm’s SmartTrack. Accelerate development and mitigate risks through expert formulation and integrated solutions. Your pathway to success starts here.
Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics
Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.
Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs
Download the Article Description: The article discusses the transition to low GWP propellants in the respiratory drug delivery sector as current high-GWP variants are phased out. The leading propellant options for the next generation of low GWP MDIs ( metered dose inhalers) are HFA 152a and HFO 1234ze from the hydro-fluoroolefin family. The article highlights […]
Nanopharm: cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
